Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Extension Study to Evaluate the Long-term Safety of GBT021601 Administered to Participants With Sickle Cell Disease Who Have Participated in a GBT021601 Clinical Trial

NCT05632354 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05632354
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05632354 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Extension Study to Evaluate the Long-term Safety of GBT021601 Administered to Participants With Sickle Cell Disease Who Have Participated in a GBT021601 Clinical Trial
Lead sponsor
Pfizer
Phase
Phase 2/3
Overall status
Terminated
Start date
January 5, 2023
Completion date
February 13, 2025
Enrollment
47 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease